38,43 €
0,06 % heute
L&S, 28. Oktober, 10:08 Uhr
ISIN
US2289031005
Symbol
AORT
Berichte

CryoLife Aktie News

Neutral
PRNewsWire
5 Tage alt
ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Neutral
PRNewsWire
15 Tage alt
30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data from the AMDS PROTECT Trial Validate Statistically Significant Positive Outcomes Demonstrated by the PERSEVERE and DARTS trials ATLANTA , Oct. 13, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a l...
Neutral
Seeking Alpha
etwa 2 Monate alt
Artivion, Inc. (NYSE:AORT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants James Mackin - Chairman, President & CEO Lance Berry - COO, CFO & Treasurer Presentation Unknown Analyst Perfect. Great. Thanks, everyone, for being with us.
Neutral
PRNewsWire
etwa 2 Monate alt
ATLANTA , Sept. 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel.
Positiv
Seeking Alpha
etwa 2 Monate alt
Artivion continues to outperform with double-digit revenue growth, strong clinical results, and share gains in niche cardiology markets despite a challenging med-tech environment. New products like AMDS, Nexus, and Arcevo, along with mechanical heart valve growth, underpin a robust outlook and potential for further upside. Clinical and regulatory wins, including FDA approvals and strong study r...
Neutral
Seeking Alpha
3 Monate alt
Artivion, Inc. (NYSE:AORT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Lance A. Berry - Executive VP of Finance & CFO Pat MacKin - Corporate Participant Conference Call Participants Daniel Walker Stauder - Citizens JMP Securities, LLC, Research Division Destiny Alexandra Hance Buch - Ladenburg Thalmann & Co. Inc., Research Division John Glenn McAulay - Stife...
Positiv
The Motley Fool
3 Monate alt
Artivion (AORT) Q2 EPS Jumps 243%
Neutral
PRNewsWire
3 Monate alt
Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis Net income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025 Adju...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen